Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib plus toripalimab for previously treated non-MSI-H metastatic colorectal cancer
ChiCTR2100048891Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donafenib and toripalimab in colorectal cancer (CRC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
donafenibtoripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100048891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048891.